KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Petmed Express (PETS) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Petmed Express (PETS) over the last 17 years, with Q4 2025 value amounting to -$21000.0.

  • Petmed Express' Capital Expenditures fell 10270.27% to -$21000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $6.3 million, marking a year-over-year increase of 5802.31%. This contributed to the annual value of $5.1 million for FY2025, which is 1334.52% up from last year.
  • Per Petmed Express' latest filing, its Capital Expenditures stood at -$21000.0 for Q4 2025, which was down 10270.27% from $2.6 million recorded in Q3 2025.
  • In the past 5 years, Petmed Express' Capital Expenditures ranged from a high of $2.6 million in Q3 2025 and a low of -$21000.0 during Q4 2025
  • Over the past 5 years, Petmed Express' median Capital Expenditures value was $988500.0 (recorded in 2022), while the average stood at $1.1 million.
  • Per our database at Business Quant, Petmed Express' Capital Expenditures skyrocketed by 29732.51% in 2023 and then crashed by 10270.27% in 2025.
  • Over the past 5 years, Petmed Express' Capital Expenditures (Quarter) stood at $294000.0 in 2021, then soared by 237.76% to $993000.0 in 2022, then increased by 13.09% to $1.1 million in 2023, then tumbled by 30.81% to $777000.0 in 2024, then crashed by 102.7% to -$21000.0 in 2025.
  • Its last three reported values are -$21000.0 in Q4 2025, $2.6 million for Q3 2025, and $1.3 million during Q2 2025.